<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03771053</url>
  </required_header>
  <id_info>
    <org_study_id>2017FC-TSYS-3042</org_study_id>
    <nct_id>NCT03771053</nct_id>
  </id_info>
  <brief_title>The Effect of Simvastatin Combined With Ezetimibe in Patients With Stable Angina and Diabetes</brief_title>
  <official_title>Intravascular Ultrasound Evaluation of the Intervention Effect of Simvastatin Combined With Ezetimibe on Coronary Borderline Lesion in Patients With Stable Angina Pectoris and Diabetes Mellitus Compared With Simvastatin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, simvastatin combined with Ezeimebum was used to enhance lipid reduction, and
      IVUS was used to evaluate the volume and composition of coronary plaque before and after
      treatment. The aim is to evaluate the overall intervention effect of Ezeimebum on stable
      angina pectoris with diabetes mellitus on the basis of statins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted in patients with stable angina pectoris complicated with diabetes
      mellitus in Chinese PLA General Hospital and coronary arteriography confirmed as critical
      lesion of coronary artery. The patients were randomly divided into two groups: ezeimebum
      combined with simvastatin group and simvastatin group. The patients of the former group were
      given ezeimebum 10mg combined with simvastatin 40mg for 12 months while the patients of the
      latter group were given simvastatin 40mg for 12 months. Assessed coronary atherosclerotic
      plaque volume percentage (PAV) and standardized total atherosclerotic plaque volume (TAV) by
      intravascular ultrasound (IVUS) at the time of entry and out of the group after 12 months.
      The changes of PAV level in both groups were taken as the main endpoints, and the changes of
      TAV levels in the two groups as the secondary endpoints. The changes of serum lipids and
      hypersensitive C-reactive protein levels were compared between the two groups before and
      after the treatment. Major cardiovascular events (non-fatal myocardial infarction, all-cause
      death, readmission to acute heart failure, and revascularization of recurrent angina
      pectoris) were followed up for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline coronary plaque volume percentage(PAV) at 12 months</measure>
    <time_frame>12 months after PCI</time_frame>
    <description>PAV=∑（(ESA CSA-lumen CSA)/(ESA CSA)）x100, EEM CSA：cross-sectional area of outer elastic membrane boundary; lumen CSA: cross-sectional area of tube boundary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline standardized coronary plaque volume(TAV) at 12 months</measure>
    <time_frame>12 months after PCI</time_frame>
    <description>TAV= (median number of images in ∑ (ESA CSA-lumen CSA) / retracement) x number of images (standardized according to the length of IVUS retracement, To ensure that each individual patient has the same weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>follow up in one year</time_frame>
    <description>Low density lipoprotein cholesterol (LDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C</measure>
    <time_frame>follow up in one year</time_frame>
    <description>High density lipoprotein cholesterol (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>follow up in one year</time_frame>
    <description>Total triglyceride(TG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TC</measure>
    <time_frame>follow up in one year</time_frame>
    <description>Total cholesterol (TC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation marker</measure>
    <time_frame>follow up in one year</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Ezetimibe with simvastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>simvastatin 40mg everyday for 12 months after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe with simvastatin</intervention_name>
    <description>ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI</description>
    <arm_group_label>Ezetimibe with simvastatin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>simvastatin 40mg everyday for 12 months after PCI</description>
    <arm_group_label>Simvastatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged 18-75 years

          -  consistent with the Chinese criteria for the diagnosis of chronic stable angina
             pectoris, stable angina pectoris symptoms in the last three months, and no more than
             CCS grade 3 of angina pectoris

          -  coronary angiography showed that the degree of coronary artery stenosis was 50% and
             70%

          -  LDL-C standard: LDL-C &gt; 80 mg/dL (2.08 mmol/L)

          -  The patients diagnosed with type 2 diabetes were currently using hypoglycemic drugs or
             insulin

          -  Sign the informed consent to join the group.

        Exclusion Criteria:

          -  Acute coronary syndromes such as myocardial infarction, unstable angina pectoris,
             variant angina pectoris, cardiac shock, chronic heart failure, malignant arrhythmia,
             etc.

          -  Patients requiring stent implantation had been treated with intensive statins prior to
             admission (e.g. doses of Atto vastatin 40mg or resuvastatin 20mg)

          -  There were contraindications or statins for statin lowering lipids or statins, and
             there was a history of adverse reactions (liver injury, rash, myolysis, etc.) in the
             use of Ezeimebum, etc.

          -  Severe liver and kidney dysfunction, creatinine clearance &lt; 30ml / min, acute
             pancreatitis, malignant tumor, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yundai Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geng Qian, MD</last_name>
    <phone>13810914587</phone>
    <email>qiangeng9396@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geng Qian, MD</last_name>
      <phone>086-01055499312</phone>
      <email>qiangeng9396@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Yun-dai Chen, MD</last_name>
      <phone>086-01055499309</phone>
      <email>cyundai@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang X, Khan AA, Haq EU, Rahim A, Hu D, Attia J, Oldmeadow C, Ma X, Ding R, Boyle AJ. Increasing mortality from ischaemic heart disease in China from 2004 to 2010: disproportionate rise in rural areas and elderly subjects. 438 million person-years follow-up. Eur Heart J Qual Care Clin Outcomes. 2017 Jan 1;3(1):47-52. doi: 10.1093/ehjqcco/qcw041.</citation>
    <PMID>28927191</PMID>
  </reference>
  <reference>
    <citation>Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9. Erratum in: Lancet. 2010 Sep 18;376(9745):958. Hillage, H L [corrected to Hillege, H L].</citation>
    <PMID>20609967</PMID>
  </reference>
  <reference>
    <citation>Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009 Aug 13;361(7):712-7. doi: 10.1056/NEJMsr0900910.</citation>
    <PMID>19675335</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.</citation>
    <PMID>26039521</PMID>
  </reference>
  <reference>
    <citation>Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004 Sep;148(3):447-55.</citation>
    <PMID>15389231</PMID>
  </reference>
  <reference>
    <citation>van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, Veltri E, Avis HJ, Kastelein JJ. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008 Oct 21;52(17):1421-9. doi: 10.1016/j.jacc.2008.09.002.</citation>
    <PMID>18940534</PMID>
  </reference>
  <reference>
    <citation>Nicholls SJ, Sipahi I. Emerging role of intravascular ultrasound in the assessment of experimental anti-atherosclerotic therapies. Curr Med Chem. 2006;13(15):1727-34. Review.</citation>
    <PMID>16787216</PMID>
  </reference>
  <reference>
    <citation>Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65. Epub 2006 Mar 13.</citation>
    <PMID>16533939</PMID>
  </reference>
  <reference>
    <citation>Nicholls SJ, Borgman M, Nissen SE, Raichlen JS, Ballantyne C, Barter P, Chapman MJ, Erbel R, Libby P. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011 Jun;27(6):1119-29. doi: 10.1185/03007995.2011.570746. Epub 2011 Mar 30.</citation>
    <PMID>21446892</PMID>
  </reference>
  <reference>
    <citation>Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.</citation>
    <PMID>22085316</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>December 7, 2018</last_update_submitted>
  <last_update_submitted_qc>December 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Qian geng</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Coronary heart disease</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

